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Background: The aim of this study was to compare the effectiveness of an educational strategy (advice to
withdraw the overused medication/s) with that of two structured pharmacological detoxification programmes in
patients with complicated medication overuse headache (MOH) plus migraine.
Methods: One hundred and thirty-seven complicated MOH patients participated in the study. MOH was defined as
complicated in patients presenting at least one of the following: a) a diagnosis of co-existent and complicating
medical illnesses; b) a current diagnosis of mood disorder, anxiety disorder, eating disorder, or substance addiction
disorder; c) relapse after previous detoxification treatment; d) social and environmental problems; e) daily use of
multiple doses of symptomatic medications. Group A (46 patients) received only intensive advice to withdraw the
overused medication/s. Group B (46 patients) underwent a standard detoxification programme as outpatients
(advice + steroids + preventive treatment). Group C (45 patients) underwent a standard inpatient withdrawal
programme (advice + steroids + fluid replacement and antiemetics preventive treatment). Withdrawal therapy was
considered successful if, after two months, the patient had reverted to an intake of NSAIDs lower than 15 days/
month or to an intake of other symptomatic medication/s lower than 10 days/month.
Results: Twenty-two patients failed to attend follow-up visits (11 in Group A, 9 in Group B, 2 in Group C, p < 0.03).
Overall, we detoxified 70% of the whole cohort, 60.1% of the patients in Group A and in Group B, and 88.8% of
those in Group C (p < 0.01).
Conclusions: Inpatient withdrawal is significantly more effective than advice alone or an outpatient strategy in
complicated MOH patients.
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Medication overuse headache (MOH) is a relevant public
health problem worldwide [1,2]. Population-based studies
in several European countries have reported prevalence
rates of MOH ranging from 0.9 to 1.8%, making it the
third most frequent headache disorder after tension-type
headache and migraine [3-7].* Correspondence: paolo.rossi90@alice.it
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in any medium, provided the original work is pMedication overuse headache has detrimental effects
on patients’ quality of life and it places a high economic
burden on society [1,2].The recently published findings
of the Eurolight project show that the mean per-person
annual costs of MOH are 3 times higher than those of
migraine and 10 times higher than those of tension-type
headache [8].
The diagnosis of MOH has been greatly facilitated by
the new appendix criteria for a broader concept of chronic
migraine, published in 2006 by the IHS [9]. These simpli-
fied criteria, which eliminate the need for headache reso-
lution or reversion to the previous episodic pattern afterOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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are helping physicians to recognise MOH and thus to re-
move the diagnostic barriers to proper care of affected
patients.
Drug withdrawal is considered the treatment of choice
for MOH, even though this view has recently been chal-
lenged [1,2,10-16]. Drug withdrawal is however approached
and performed very differently within and across countries.
Furthermore therapeutic recommendations for the acute
phase of detoxification vary considerably between studies
[1,2,17-19]. Other reasons for the heterogeneity in MOH
management are the shortage of controlled treatment stud-
ies, meaning that treatment recommendations are based
mainly on expert opinions rather than on solid scientific
evidence [20], and the fact that MOH is, in many respects,
a heterogeneous disorder. MOH group indeed encompasses
a spectrum of conditions that vary in terms of phenotypical
characteristics, type and amount of drugs overused, comor-
bidities and response to prophylactic treaments. In order to
improve the management of MOH, some authors have
pragmatically suggested to subdivide MOH into two clinical
subtypes: simple and complex [21-23]. In accordance with
this approach we previously demonstrated that in MOH
patients with low medical needs and migraine as the pri-
mary headache type advice and education were as effective
as structured inpatient and outpatient detoxification pro-
grammes in achieving withdrawal of the overused medica-
tion/s [24]. More recently, other groups studying “mildly”
affected MOH populations have confirmed the effectiveness
of brief educational intervention alone in reducing medica-
tion overuse and headache chronification and also the simi-
lar efficacy between inpatient and outpatient programmes
[25-27]. These studies thus lend support to the recom-
mendation that uncomplicated MOH should, in the first
instance, be tackled through outpatient withdrawal pro-
grammes [14,20,26-28]. Conversely, complicated forms,
such as those with opioids, barbiturates or benzodiaze-
pines overuse, or presenting psychological problems or
medical comorbidities that could impact on outpatient
withdrawal, are generally considered for inpatients with-
drawal, as are those who have previously failed outpatient
detoxification programmes or who lack the necessary mo-
tivation [14,17,18,27]. In partial support of the simple-vs-
complex approach, we showed in a previous study that
educational intervention alone is significantly more effec-
tive in patients with simple MOH as opposed to patients
with complicated MOH (92.1% vs 65.3% of responders, re-
spectively); although the level of adherence to treatment
did not differ between the two groups [24] and notwith-
standing the fact that a success rate of 65.3% was obtained
in complicated MOH.
The aim of this study was to compare the effectiveness
of a simple withdrawal strategy, based exclusively on in-
tensive advice to withdraw the overused medication/s,with that of two structured pharmacological detoxification
programmes in a cohort of patients with complicated
MOH in whom migraine was the primary headache type.Methods
For the purpose of this study, complicated MOH was
defined by the presence of at least one of the following
conditions [29]: a) comorbidity with other clinically rele-
vant painful condition (e.g. chronic painful disorders such
as fibromyalgia or low back pain, neuropathic pain, etc.);
b) ongoing or recent comorbidity with psychiatric dis-
orders (i.e. mood disorder, anxiety disorder, substance ad-
diction disorder or eating disorder), as assessed by the
Structured Clinical Interview for DSM-IV Axis I Disor-
ders (SCID-I), Clinician Version [30]; c) moderate/severe
psychosocial and environmental problems as defined by
DSM-IV Axis IV, assessed at the end of the initial visit by
means of a structured interview; d) daily, or almost daily,
use of multiple doses of symptomatic medication/s (more
than 3 doses/day of analgesics or more than 2 doses/day
of triptans, ergots, combinations of acute medications, or
analgesics in combination) or anticipatory use of symp-
tomatic medication/s; e) relapse into overuse following
previous detoxification treatment.
This set of criteria for defining complicated MOH was
deemed to represent the best combination of existing cri-
teria (already proposed in the literature) and the authors’
personal experience in managing MOH patients attending
headache centres in Italy, and it has already proved to be
highly sensitive in identifying MOH patients in whom ef-
fective drug withdrawal may be obtained through the
imparting of advice alone [29].
It has been established that abrupt discontinuation of an
overused medication may lead to serious withdrawal symp-
toms such as hypotension, tachycardia, vomiting, intense
nervousness, sleep disturbances and even hallucinations
and seizures, particularly in patients overusing opioids, bar-
biturates and tranquillisers, and that these symptoms are
best treated under medical supervision in patients with
significant complicating medical conditions [1,14,19,20].
Therefore, for ethical reasons, in this study we excluded
patients with severe major depression and/or severe psychi-
atric illnesses and those likely to encounter problems as
withdrawal treatment outpatients. Thus, the final set of ex-
clusion criteria were: a) co-existent severe medical (e.g. un-
controlled arterial hypertension, uncontrolled diabetes
mellitus, ischaemic cardiopathy, etc.) or psychiatric illness;
b) overuse of opioids and/or barbiturate-containing agents;
c) treatment with migraine prophylactic drugs within the
past three months; d) pregnancy or breastfeeding.
Consecutive new patients, aged 16–65 years, affected
by complicated MOH [29] in whom the primary head-
ache was migraine attending a specialist headache centre
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an eighteen-month period (July 2009 to December 2010).
The patients were evaluated prospectively and the
study lasted 14 weeks for each subject (Figure 1). After
the first visit, eligible subjects were asked to keep a diag-
nostic headache diary for four weeks, simply recording
their headache pattern and drug use (baseline period).
This period was purely observational and at this time no
diagnosis or therapeutic indications were given. At the sec-
ond visit, at the end of this baseline period, the patients
still fulfilling the inclusion criteria were randomly assigned
(using a computer-generated random number sequence),
in equal numbers, to three different treatment groups [24].
Group A received only advice to withdraw the overused
medication/s; Group B underwent a standard outpatient
detoxification programme consisting of: 1) advice to
abruptly withdraw the overused medication/s, 2) prednis-
one p.o. during the first 10 days (60 mg/day, 2 days;
40 mg/day, 2 days; 20 mg/day, 6 days) [24], 3) individua-
lised preventive treatment begun on day 1 (the preventive
agent was chosen on the basis of side-effect profile, comor-
bid conditions, the patient’s needs and preferences, and
the patient’s previous therapeutic experiences). Group CRandomisation (n=137) 
Group A = simple advice (n=4
Group B = structured outpatien
Group C = structured inpatien
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Figure 1 Outline of the trial.underwent a standard inpatient detoxification programme.
After receiving advice about the need to withdraw symp-
tomatic medications, patients in this group were admitted
as inpatients to the INI Grottaferrata Headache Clinic for
a 10-day period during which they received: 1) abrupt dis-
continuation of the overused medication/s, 2) close obser-
vation and support for 8–10 days, 3) prednisone p.o.
(60 mg/day, 2 days; 40 mg/day, 2 days; 20 mg/day, 6 days),
4) individualised preventive treatment as from day 1, and
5) parenteral fluid replacement and administration of an-
tiemetics (metoclopramide i.v).
In order to standardise the educational part of the
treatment programme, all advice was issued by the same
physician (PR). The advice to discontinue the overused
medication/s was given verbally [24] and its imparting,
which took about 15 minutes during the second consult-
ation, was structured as follows: a) the role of medication
overuse in making headache chronic and in reducing the
effectiveness of preventive and behavioural treatments
was explained; b) the phenomenon and symptoms of
withdrawal headache were explained in detail; c) the bene-
ficial long-term effects, on migraine natural history, of re-
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term pain relief) were emphasised; d) anticipatory use of
medication was discouraged; and e) the superiority of the
detoxification programme over other therapeutic options
was emphasised. In patients assigned to Group A the
physician emphasised the importance, for patients, of
playing an active role in the management of their head-
ache, without relying solely on medication.
For the treatment of withdrawal headache and asso-
ciated symptoms, patients could be prescribed the follow-
ing acute drugs, according to their personal medical
history (the rationale was that patients should not use the
drug that she or he had previously been abusing) and
headache characteristics:
a) Antiemetics (metoclopramide 10 mg i.m. or p.o.1 to 3
times per day; chlorpromazine, 25–50 mg i.m. or p.o.,
domperidone 30 mg rectally or 10 mg p.o.), and (with
intake limited to no more than two days per week)
b)Acetaminophen (1000 mg p.o. or rectally or i.v on
demand, maximum dosage 3 g × day) or naproxen
(500 mg p.o. or p.r., maximum dosage 1000 mg ×
day) or indomethacin (100 mg p.o. or p.r., or 50 mg
i.m., maximum dosage 200 mg × day)
c) Eletriptan 40 mg p.o., frovatriptan 2.5 mg p.o.,
almotriptan 12.5 mg p.o., or rizatriptan 10 mg p.o.
Furthermore, the patients were asked to fill in a detailed
diagnostic headache diary. The patients assigned to out-
patient treatment groups were also told that they could
contact the headache centre for medical help and support,
should this be needed.
Follow-up visits were scheduled during the 5th and the
10th week after the start of the detoxification programme.
All patients failing to attend the follow-up visits were
called by telephone within three months from the start of
the detoxification programme in order to ascertain their
reasons for not adhering to the treatment programme. As
in our previous studies [24,29], the patients were not
informed that they were included in a study assessing the
effectiveness of simple advice as a withdrawal strategy for
MOH. This approach was authorised by the ethics com-
mittee of our institute. Therefore, no signed, informed
consent was obtained. The research was in compliance
with the Helsinki Declaration.
Outcome measures
The primary outcome measures were: a) responders
(number of), defined as those subjects who, two months
after the start of withdrawal of the overused drug/s, had
reverted to an intake of NSAIDs lower than 15 days/
month or to an intake of other symptomatic medication/s
lower than 10 days/month; b) adherence to the treatment,
expressed as the number of patients who completed thefollow-up visits; c) responders with headache improve-
ment (number of), defined as those patients who, two
months after the start of the drug withdrawal, experienced
more than 50% reduction in headache frequency from
baseline.
As secondary outcome measures we considered the
percentage reduction, two months after the start of the
withdrawal, in the number of headache days/month, the
number of days with use of symptomatic medication/
month, and the number of symptomatic medications/
month.
Power calculation and statistical analysis
The main target parameter was the number of responders.
On the basis of the results of previous studies, we
assumed a responder rate of 55% in the no-intervention
group and of 90% in the structured intervention groups, i.
e. the study had to have the power to detect a difference
of 35%. In applying the above-mentioned percentages,
using a power of 0.8% and a significance level of 5%, a
minimum of 35 patients per treatment group was required
(Fisher’s exact test, two-tailed). We thus needed a total of
105 patients to complete the study. Given the impossibil-
ity of performing a satisfactory a priori analysis of the
other outcome measures, the adherence to treatment
criterion and the other target criteria were subjected to
exploratory statistical analysis.
Multi-group comparisons were performed using the
one-way analysis of variance for continuous variables and
the non-parametric Kruskal-Wallis test for non-normally
distributed data. The chi-square test and Fisher’s exact
test with Freeman-Halton extension (when applicable)
were used for multi-group comparisons of categorical
variables. Given that we were performing multiple testing,
the level of significance was set at p < 0.025. The analysis
was carried out using SPSS 11 for Windows (SPSS Inc.,
Chicago, IL).
Results
One hundred and fifty-one patients were evaluated during
the study period; 10 were excluded because they did not
meet the inclusion criteria (four of these overused butalbi-
tal containing agents, no one overuse opioids). Of the
remaining 141 patients, included in the study, four with-
drew during the baseline period. Table 1 presents the
demographic and clinical characteristics of the patients
randomised to the three different detoxification groups. Of
the 137 patients forming the final sample, 110 were females
(80.3%) and 27 (19.7%) were males, mean age 46±12 years.
Forty-eight patients (35%) overused NSAIDs, 31 (22.7%)
overused NSAIDs in combination (in all cases indometh-
acin plus caffeine plus prochlorperazine), three (2.2%) over-
used ergots, 37 overused triptans (27%), and 18 (13.1%)
overused combinations of acute medications (14 used
Table 1 Demographics and headache characteristics of the study population
Group A (n = 46) Group B (n = 46) Group C (n = 45) Statistics
Sex n° (%) NS§
F 39 37 34
M 7 9 11
Age mean ± SD (yrs) 44.9 ± 11 46.2 ± 12 46.3 ± 11.4 NS¤
(median) (48) (48) (49)
Educational level n° (%)
Secondary school or above 30 31 27 NS§
Primary or middle school 16 15 18
Employed n°(%)
Yes 29 28 25 NS§
No 17 18 20
Marital status n° (%)
Single 8 7 5 NS§
Married 32 32 35
Widowed/divorced 6 7 5
Migraine subtype n° (%)
With aura 5 3 5 NS*
Without aura 41 43 40
Duration of migraine
mean±SD (yrs) 25.8 ± 12.8 26.0 ± 12 26.1 ± 11.7 NS¤
(median) (29) (29) (30)
Duration of MOH
mean±SD (yrs) 3.3 ±3.3 2.9 ± 3.1 3.4 ± 2.9 NS¤
(3) (2) (3)
Number of headache days/month
mean±SD 24.9 ± 6 25.4 ± 6.7 25.4 ± 6.4 NS¤
(median) (30) (30) (30)
Number of days with use of symptomatic medication/month
mean±SD 23.9 ± 5.4 24.1 ± 4.8 24.3 ± 4.9 NS¤
(median) (30) (30) (30)
Overused drugs n (%): NS*
• Analgesics 16 14 18
• Ergotamine 1 1 1
• NSAIDs in combination 10 11 10
• Combination of acute medications 6 6 6
• Triptans 13 14 10
Number of overused medications/month NS¤
mean ±SD 37.2 ± 28.4 36.9 ± 32.4 38.2 ± 31
(median) (38) (38) (40)
NS = not significant, *Fisher’s test, § Chi-square test, ¤ Kruskal-Wallis test.
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tans, 1 used triptans + ergotamine). Sociodemographic
variables, migraine subtype, migraine duration, MOH du-
ration, number of headache days per month, and number
and type of overused medication(s) did not differ signifi-
cantly between the three groups (Table 1). Table 2 shows
the prevalence of the different factors complicating MOH
in the three groups of patients.
In group B, 16 patients received valproic acid (500–
1000 mg/day) as preventive medication, 11 received beta-
blockers (metoprolol 100–200 mg/ day), nine received
amitriptyline (25–75 mg/day), and 10 received topiramate
(75 mg/day). In group C, 17 patients received valproic acid
(500–1000 mg/ day) as preventive medication, eight re-
ceived beta-blockers (metoprolol 75–100 mg/ day), eight
received amitriptyline (30–60 mg/ day) and 12 received
topiramate (50–75 mg/ day).
Twenty-two patients (16%) dropped out of the study
(11 in Group A, 9 in Group B and 2 in Group C, p < 0.025,
Table 3). The reasons given for missing follow-up visits
were: lack of time (two in Group A, two in Group B, all at
the first follow-up), lack of motivation (two in Group A,
one in Group B, one in Group C, all at the first follow-up),
the decision to seek other medical help (three in Group A,
one in Group B, both at the first follow-up), fear of side
effects (one in Group A, two in Group B, both at the first
follow-up), health problems (one in Group A, one in group
C, both at the second follow-up) and worsening of head-
ache (two in Group A, three in Group B, both at the first
follow-up). No differences in headache characteristics or
demographics were found between the patients from the
three groups completing and not completing the follow-up
visits (all, p > 0.025).
After two months, 115 patients had completed the
follow-up visits (35 in Group A, 37 in Group B, 43 in
Group C). Of these, 96 (84.2%) were considered respondersTable 2 Prevalence of clinical factors defining MOH as compli
Group A (n = 4
Psychiatric comorbidity n° (%) 26 (56.5%)
• Anxiety disorder 16 (34.7%)
• Mood disorder 21 (45.6%)
• Anxiety and mood disorder 10 (21.7%)
• Eating disorder 3 (6.5%)
Psychiatric comorbidity alone 8 (17.4%)
Psychosocial and environmental problems n° (%) 16 (34.7%)
Psycho-social and environmental problems alone 6 (13%)
Relapsers n° (%) 6 (13%)
Daily use of multiple drugs n° (%) 11 (23%)
Medical illnesses n° (%)** 4 (8.7%)
*Fisher’s test, § Chi-square test.
**chronic low back pain = 2, fibromyalgia =2, recent intervention for colon cancer =
NS = not significant.(28 in Group A, 28 in Group B, 40 in Group C, p = 0.003,
Table 3). Of all the patients included in the study we suc-
cessfully detoxified 70% (60.8% in Groups A and B, and
88.9% in Group C, p = 0.003 Table 3). At two months, 25
patients in Group A (56.5%), 26 in Group B (56%) and 38
in Group C (84.4%) recorded a more than 50% reduction
in headache frequency from baseline (p = 0.003) and were
thus considered responders with headache improvement.
In the patients completing the study, the percent reduc-
tion in the number of headache days/month was 44 ± 25
in Group A, 49.8 ± 28 in Group B and 73 ± 22 in Group C
(p < 0.001). The percent reduction in the number of days
with use of symptomatic medication was 62.5 ± 23 in
Group A, 63.6 ± 26 in Group B, and 75.2 ± 23 in Group C
(p < 0.001). The percent reduction in the number of symp-
tomatic medications/month was 68,1 ± 18 in Group A,
69.7 ± 22 in Group B and 84.3 ± 20 in Group C (p < 0.001)
Discussion
The main finding of this study was that a structured in-
patient detoxification programme was more effective, in
the short-term, than advice alone or than a structured out-
patient programme in achieving withdrawal of the over-
used medication(s) in patients with complicated MOH
who had migraine as their primary headache type. In
addition, contrary to the pattern emerging in simple MOH
[24], outpatient strategies were associated with a lower
level of adherence to treatment: 21.8% of the patients allo-
cated to outpatient strategies did not complete the study,
whereas only 4.6% of the patients allocated to the inpatient
programme dropped out of the study.
As in previous studies, conducted in patients with sim-
ple or mild MOH [14,24,25], early administration of a pre-
ventive treatment in an outpatient setting did not improve
the effectiveness of the withdrawal treatment when com-
pared with simple advice to withdraw the overused drugcated
6) Group B (n = 46) Group C (n = 45) Statistics
26 (56.5%) 30 (66.6%) NS*
17 (36.9%) 19 (42.2%)
21 (45.6%) 22 (48.8%)
10 (21.7%) 11 (24.4%)
2 (4.3%) 3 (6.6%)
8 (17.4%) 11(24.4%)
10 (21.7%) 12 (26.6%) NS*
4 (8.7%) 4(8.8%)
9 (19.5%) 8 (17.7%) NS§
17 (36.9%) 17 (37.7%) NS§
2 (4.3%) 2 (4.4%) NS*
1, severe obesity = 2, chronic C hepatitis on antiretroviral therapy = 1,








Patients missing follow-up visits n(%) 11 (23.9) 9 (19.5) 2 (4.4) p < 0.025*
Responders n(%) 28 (60.8) 28 (60.8) 40 (88.9) p = 0.003*
Responders with headache improvement n (%) 25 (54.3) 26 (56.5) 38 (84.4) p = 0.003§
Percent reduction in number of headache days/month mean ± SD (median) 44 ± 25 (50) 49.8 ± 28 (52) 73 ± 22 (76) p < 0.001¤
Percent reduction in the number of days with use of symptomatic medication
mean ± SD (median)
62.5 ± 23 (64) 63.6 ± 26 (64) 75.2 ± 23 (78) p = 0.001¤
Percent reduction in the number of symptomatic medication mean ± SD (median) 67.8 ± 18 (68) 69.7 ± 22 (70) 83.3 ± 20 (84) p = 0.001
*Fisher’s test, § Chi-square test, ¤ Kruskal-Wallis test.
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in our complicated MOH patients, made the difference
versus the other detoxification strategies in both respon-
ders and adherence to treatment measures. This is prob-
ably because the inpatient approach allowed a more strict
control of medication intake, the prompt and inten-
sive treatment of withdrawal symptoms, a better patient
support, and isolation of patients from the socio-
environmental pressures liable to reinforce drug overuse
behaviour.
In the recently published EFNS headache panel guide-
line on the treatment of MOH [20], the authors concluded
that “the type of withdrawal strategy (inpatient, outpatient,
advice alone) does not influence the success of the treat-
ment and the relapse rate in general” (level A recommen-
dation). Two more recent studies, conducted in Europe,
seem to support this statement [27,28]. Creac’h et al. com-
pared the efficacy of inpatient and outpatient withdrawal
programmes in 82 consecutive patients with MOH in an
open-label prospective randomised trial. The finding that
hospitalisation did not improve either the short or the
long-term prognosis of these patients prompted the
authors to recommend outpatient withdrawal in the first
instance in patients with MOH [27]. Munksgaard et al.
investigated the effectiveness of two structured outpatient
detoxification programmes in 98 treatment-resistant
patients with MOH, i.e. patients previously unsuccessfully
treated by specialists [28]. Both programmes proved to be
highly effective in the short and the long term, which sug-
gests that most MOH patients, even those regarded as
treatment-resistant, may be cured in an outpatient setting.
However, these two studies [27,28], like all the previous
research comparing different approaches to withdrawal
therapy [14,20], did not include patients with complicated
MOH as defined herein. The present study, in which hos-
pitalisation was found to be superior to outpatient strat-
egies, is thus the first to investigate the efficacy of different
withdrawal strategies in complicated MOH. Nevertheless,
it is worth noting that, as in our previous study [29],
simple educational intervention alone proved sufficient todetoxify the majority (60%) of the complicated MOH
patients and 80% of the patients completing the study.
These data suggest that compliance with outpatient stra-
tegies is the main problem in complicated MOH patients,
given that almost 20% of them were somewhat dissatisfied
by an approach based essentially on the imparting of ad-
vice to withdraw the symptomatic drug/s. A recent study
showed that MOH patients request information about the
disease and want to know how they might actively partici-
pate in the treatment of it [31]. It is possible, therefore,
that compliance might be improved by taking patient
preferences into account when choosing the withdrawal
programme [27]. In view of hospitalisation costs, particu-
larly in the current economic climate, our experience with
complicated MOH patients [29] suggests that advice to
withdraw the overused medication/s, on the basis of its ef-
fectiveness, safety and cost [14], should be the first step in
a step-care approach to MOH management that takes into
account patients’ preferences. In case of failure, inpatient
detoxification should be offered in order to grant a higher
rate of success. This approach seems the most adequate
one based on the present and on published data, at least
until convincing evidence is provided in favour of a strati-
fied approach in which patients are assigned to different
treatments according to the extent of their medical needs.
Several possible limitations of our study preclude the
drawing of definite conclusions regarding the use of sim-
ple advice as a withdrawal strategy for MOH. The head-
ache clinic setting may have favoured the productive
doctor-patient alliance that is essential for successful
educational interventions. Thus, the reproducibility of
our findings in different settings, such as primary care,
remains uncertain.
Furthermore, the classification of MOH patients into
simple and complicated subtypes is not immediate and
requires the administration of time-consuming structured
interviews by experienced physicians. Recent work in
Norway with the Severity of Dependence Scale (SDS) sug-
gests that this simple and validated questionnaire is useful
for predicting the outcome of MOH after an educational
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SDS might be a helpful tool for identifying MOH patients
with higher medical needs.
Third, this study included only MOH patients who had
migraine as their primary headache; these patients have a
better prognosis than those with other headache types,
such as tension-type headache [1,14].
Finally, the proposed criteria for medical comorbidity
(the presence of coexistent significant and complicating
medical illnesses) might benefit from a more accurate
definition deriving from reproducibility study involving
different physicians.
Conclusions
Inpatient withdrawal is significantly more effective than
advice alone or an oupatient strategy in complicated
MOH patients.
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